Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acarbose effects on incretin secretion in newly diagnosed type 2 diabetes
ChiCTR-TCC-09000412Phase 4Completed
- Sponsor
- Guangdong Provincial People's Hospital
- Start
- Oct 2008
- Modality
- Microbiome-Derived Products → Microbiome Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of acarbose in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Guangdong Provincial People's Hospital. Primary endpoints: Plasma fasting glucose, 2-hour postprandial glucose and 5 more. Started Oct 2008; status: completed.
02
Drugs
acarbose
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR-TCC-09000412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TCC-09000412.